Stock Market Reviews

GPCR (Structure Therapeutics Inc.) News

Get the latest news, insights, and market updates on GPCR (Structure Therapeutics Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
  SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at
  Dec 10, 2025 - $GPCR
• Why Structure Therapeutics Stock Doubled and Then Some on Monday
  The company's investigational GLP-1 treatment performed admirably well in a phase 2b study.
  Dec 9, 2025 - $GPCR
• Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial
  We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to a new 52-week high on Monday after announcing stellar topline results from its ongoing clinical program to test the efficacy of its therapy candidate, aleniglipron, […]
  Dec 9, 2025 - $GPCR
• In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?
  In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.
  Dec 9, 2025 - $GPCR
• Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar
  Dyne is readying a competitor to Sarepta’s Exondys 51. Elsewhere, a pair of obesity drugs showed promise and Kymera’s protein-degrading medicine displayed “biologic-like or better efficacy,” according to one analyst.
  Dec 8, 2025 - $GPCR
• Top Midday Stories: Paramount Launches $30-per-Share Bid for Warner Bros. Discovery; IBM to Acquire Confluent in $11 Billion Deal
  All three major US stock indexes were down in late-morning trading Monday, as investors look ahead t
  Dec 8, 2025 - $GPCR
• Top Midday Gainers
  Top Wealth Group (TWG) disclosed late Friday a "positive" outlook for the financial year ending Dec.
  Dec 8, 2025 - $GPCR
• Structure Therapeutics Shares Surge on Positive Phase 2b Results for Obesity Drug Aleniglipron
  Structure Therapeutics (GPCR) shares almost doubled in recent Monday trading after the company repor
  Dec 8, 2025 - $GPCR
• Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
  Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) observed with 240 mg dose in the exploratory ACCESS II study at 36 weeks No adverse event-related treatment discontinuations observed when starting at lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study Data comprehensively support and inform advance
  Dec 8, 2025 - $GPCR
• Structure Therapeutics (GPCR): Assessing Valuation as ACCESS Obesity Trial Readout Draws Investor Focus
  Structure Therapeutics (GPCR) is stepping into the spotlight as it prepares to release topline data from its ACCESS trial of aleniglipron, an oral GLP 1 candidate for obesity, along with a same day investor call. See our latest analysis for Structure Therapeutics. The ACCESS data drop caps a volatile year, with a 90 day share price return of 62.64% signaling building momentum, even though the 1 year total shareholder return is still slightly negative. If this GLP 1 readout has you thinking...
  Dec 8, 2025 - $GPCR